CUREVAC NV
NASDAQ: CVAC (CureVac N.V.)
Last update: 8 hours ago5.03
-0.09 (-1.76%)
| Previous Close | 5.12 |
| Open | 5.12 |
| Volume | 1,378,677 |
| Avg. Volume (3M) | 533,296 |
| Market Cap | 1,132,619,008 |
| Price / Earnings (TTM) | 5.08 |
| Price / Earnings (Forward) | 5.24 |
| Price / Sales | 12.71 |
| Price / Book | 1.03 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Profit Margin | 34.50% |
| Operating Margin (TTM) | -6,128.33% |
| Diluted EPS (TTM) | 0.930 |
| Quarterly Revenue Growth (YOY) | -92.80% |
| Total Debt/Equity (MRQ) | 5.78% |
| Current Ratio (MRQ) | 7.65 |
| Operating Cash Flow (TTM) | 157.03 M |
| Levered Free Cash Flow (TTM) | 92.39 M |
| Return on Assets (TTM) | 19.92% |
| Return on Equity (TTM) | 33.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | CureVac N.V. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | 0.63 |
|
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 57.37% |
| % Held by Institutions | 4.70% |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |